Abstract
In the absence of comprehensive position papers from professional organizations on the complex issue of patient affordability of biologic therapies, the Jefferson School of Population Health reconvened a National Advisory Board to discuss the issue. The objectives of the board were to quantify the issues and to identify potential solutions - including a recommended approach for payers.